<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The effect of cardiac resynchronization therapy (CRT) on left ventricular wall thickness and left ventricular mass (LVM) is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVES: To evaluate the effects of CRT on septal and posterior wall thickness (SWT and PWT) and LVM in patients with <z:hpo ids='HP_0011713'>left bundle branch block</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e>) and non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> vs implantable cardioverter-defibrillator patients and to assess the relationship between CRT-induced changes and cardiac events </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We investigated 843 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> and 366 patients with non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> enrolled in the Multicenter Automatic Defibrillator Implantation Trial - Cardiac Resynchronization Therapy (MADIT-CRT) trial to analyze changes in SWT, PWT, and LVM at 12 months and subsequent outcome </plain></SENT>
<SENT sid="3" pm="."><plain>The primary end point was <z:hpo ids='HP_0001635'>heart failure</z:hpo> or <z:hpo ids='HP_0011420'>death</z:hpo>; secondary end points included <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>, <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo>, or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> patients, reduction in SWT, PWT, and LVM was more pronounced in CRT defibrillator (CRT-D) than in implantable cardioverter-defibrillator (SWT:-6.7% ± 4.4% vs-1.0% ± 1.9%; PWT:-6.4% ± 4.3% vs-0.8% ± 1.9%; LVM:-23.6% ± 9.9% vs-5.1% ± 5.1%; P&lt;.001 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>In CRT-D patients with non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e>, LVM reduction was less pronounced; however, changes in SWT and PWT were comparable </plain></SENT>
<SENT sid="6" pm="."><plain>Changes in LVM correlated with changes in left ventricular end-diastolic volume </plain></SENT>
<SENT sid="7" pm="."><plain>In CRT-D patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e>, reduction in SWT and LVM was associated with reduction in <z:hpo ids='HP_0001635'>heart failure</z:hpo>/<z:hpo ids='HP_0011420'>death</z:hpo> (SWT: hazard ratio 0.94; 95% confidence interval 0.89-0.99 per percent change; P = .03) and <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo>/<z:hpo ids='HP_0011420'>death</z:hpo> (SWT: hazard ratio 0.95; 95% confidence interval 0.91-1.00; P = .04) </plain></SENT>
<SENT sid="8" pm="."><plain>CRT-D patients with non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> did not show favorable reduction in clinical or arrhythmic end points related to changes in SWT, PWT, or LVM </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: CRT-D was associated with significant reduction in SWT, PWT, and LVM in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> along with left ventricular volume changes and associated favorable clinical and <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> outcomes </plain></SENT>
</text></document>